Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity
Severe neurological and endocrine toxicities are well recognised adverse events of immune checkpoint inhibitors. However, the underlying pathophysiology is poorly understood, and classical circulating markers are often non-informative, making it difficult to obtain a precise diagnosis and to initiate timely and effective treatment. Here we investigated immune-modulating activity in the plasma of a mesothelioma patient who developed fatal neuroendocrine toxicity characterised by insulin-dependent diabetes, hypophisitis and a myasthenia-like syndrome while on treatment with the dual PD1 and TIM3 blockade.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Luca Mazzarella, Silvia Giugliano, Paolo D'Amico, Carmen Belli, Bruno Achutti Duso, Maria Rescigno, Giuseppe Curigliano Tags: Original Research Source Type: research
More News: Asbestosis | Brain | Cancer | Cancer & Oncology | Diabetes | Endocrinology | Insulin | Mesothelioma | Neurology | Toxicology